Nuveen LLC Purchases New Position in Amicus Therapeutics, Inc. $FOLD

Nuveen LLC bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 3,522,217 shares of the biopharmaceutical company's stock, valued at approximately $28,741,000. Nuveen LLC owned about 1.14% of Amicus Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of FOLD. Vestal Point Capital LP bought a new position in Amicus Therapeutics in the 4th quarter worth $31,557,000. Orbimed Advisors LLC raised its holdings in Amicus Therapeutics by 300.7% in the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock worth $21,528,000 after purchasing an additional 1,715,100 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in Amicus Therapeutics by 107.9% in the 4th quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock worth $24,487,000 after purchasing an additional 1,349,145 shares in the last quarter. Prosight Management LP bought a new position in Amicus Therapeutics in the fourth quarter worth about $8,666,000. Finally, D. E. Shaw & Co. Inc. raised its stake in Amicus Therapeutics by 132.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,560,410 shares of the biopharmaceutical company's stock worth $14,699,000 after buying an additional 889,968 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently issued reports on FOLD. The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, UBS Group increased their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Up 2.1%

FOLD stock traded up $0.1550 on Thursday, reaching $7.5550. 1,398,770 shares of the company traded hands, compared to its average volume of 3,867,496. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The company has a market cap of $2.33 billion, a P/E ratio of -62.95 and a beta of 0.53. The firm has a fifty day simple moving average of $6.29 and a 200-day simple moving average of $7.23.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.